AMALY — SHARIAH COMPLIANCE REPORT
==================================
Symbol: ONCO
Report Date: 2026-04-02
Full Report: https://amaly.io/stock/ONCO

EXECUTIVE SUMMARY
------------------
Compliance Status: NON_COMPLIANT
Quality Rating: B
Description: ONCO, a biotechnology company in an unknown industry and sector, fails key Shariah financial screening criteria due to excessive debt and interest income ratios. The core business in oncology diagnostics is permissible, but financial structure raises significant riba concerns. No inclusion in major Shariah indices confirms non-compliance status. Purification requirements are elevated due to high impure income, and ESG factors show low risk with no controversies. Investors should monitor for financial improvements.

Primary Compliance Concerns:
- Debt ratio: 136.17% exceeds all thresholds (AAOIFI 30%, MSCI 33.33%, S&P 33%)
- Interest income ratio: 128.66% exceeds 5% threshold across standards

Purification Requirement: 128.66%
Index Inclusion: Not included in any major Shariah indices (S&P, MSCI, FTSE, DJIM)

KEY FINANCIAL METRICS
----------------------
Debt Ratio: 136.2%
Liquidity Ratio: 23.7%
Interest Income Ratio: 128.7%
Purification Required: 0.00%

INDEX INCLUSION STATUS
-----------------------
S&P Shariah: EXCLUDED
MSCI Islamic: EXCLUDED
DJIM: EXCLUDED
FTSE Shariah: EXCLUDED
Total: 0 of 4
Last Verified: 2025-12-15

REPORTING PERIOD
-----------------
Latest Annual Report: FY 2025
Latest Quarterly Data: Q3 2025
Trend Period: FY 2020 to FY 2025
Data Retrieved: 2026-02-14T12:00:00Z

---
Full interactive report: https://amaly.io/stock/ONCO
Provided by Amaly (https://amaly.io) — Shariah Compliant Stock Screener
Disclaimer: This data is for informational purposes only and does not constitute financial or religious advice.